Drawing on current data and clinical experience, Dr Wilkins highlights the importance of thoughtful patient selection and lesion-specific decision-making to maximize outcomes.
Drawing on current data and clinical experience, Dr Wilkins highlights the importance of thoughtful patient selection and lesion-specific decision-making to maximize outcomes.
Dr Wahood discusses trends reshaping the landscape of mechanical thrombectomy for acute ischemic stroke, particularly in patients with atrial fibrillation.
Dr Wahood discusses trends reshaping the landscape of mechanical thrombectomy for acute ischemic stroke, particularly in patients with atrial fibrillation.
Dr Dania Daye discusses the need for standardized reporting in AI studies and reflects on key themes from her recent keynote at the Society of Interventional Oncology (SIO) conference.
Dr Dania Daye discusses the need for standardized reporting in AI studies and reflects on key themes from her recent keynote at the Society of Interventional Oncology (SIO) conference.
Dr. Srini Tummala outlines the essential components of a high-quality noninvasive vascular assessment for patients with chronic limb-threatening ischemia.
Dr. Srini Tummala outlines the essential components of a high-quality noninvasive vascular assessment for patients with chronic limb-threatening ischemia.
The EU Joint Action Networks of Expertise on Cancer (JANE-2) green paper examines emerging applications and strategies for integrating physical tumor ablation methods into oncology care.
The EU Joint Action Networks of Expertise on Cancer (JANE-2) green paper examines emerging applications and strategies for integrating physical tumor ablation methods into oncology care.
SALT LAKE CITY, Utah — August 6, 2026 — Fluidx Medical Technology, Inc., a developer of innovative embolic technologies, today announced the successful closing of financing to fund development and growth. The financing follows significant...
SALT LAKE CITY, Utah — August 6, 2026 — Fluidx Medical Technology, Inc., a developer of innovative embolic technologies, today announced the successful closing of financing to fund development and growth. The financing follows significant...
Adding selective radiofrequency ablation after transarterial chemoembolization significantly improved survival outcomes among patients with liver-confined, unresectable hepatocellular carcinoma, according to the phase 3 TORCH randomized...
Adding selective radiofrequency ablation after transarterial chemoembolization significantly improved survival outcomes among patients with liver-confined, unresectable hepatocellular carcinoma, according to the phase 3 TORCH randomized...
The announcement follows successful results in a multi-site clinical study with U.S. Renal Care, one of the nation's largest dialysis providers, showing early clinical validation of VxWave in routine dialysis clinic workflows.
The announcement follows successful results in a multi-site clinical study with U.S. Renal Care, one of the nation's largest dialysis providers, showing early clinical validation of VxWave in routine dialysis clinic workflows.
Salt Lake City (UT) – 07/24/2026 Fluidx Medical Technology, Inc., a clinical stage medical device company advancing its portfolio of embolic technologies, announced that it recently submitted to the U.S. Food and Drug Administration (FDA) the...
Salt Lake City (UT) – 07/24/2026 Fluidx Medical Technology, Inc., a clinical stage medical device company advancing its portfolio of embolic technologies, announced that it recently submitted to the U.S. Food and Drug Administration (FDA) the...
ALAMEDA, Calif. – Penumbra, Inc. announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company’s novel...
ALAMEDA, Calif. – Penumbra, Inc. announced the results of THUNDER, an Investigational Device Exemption (IDE) study, to evaluate the safety and effectiveness of THUNDERBOLT™, the company’s novel...
CAMPBELL, Calif., July 16, 2026 — Imperative Care, a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the launch of the Ikon™ 24 Pro Guidewire, a next-generation...
CAMPBELL, Calif., July 16, 2026 — Imperative Care, a medical technology company focused on advancing treatments for patients suffering from thromboembolic disease, today announced the launch of the Ikon™ 24 Pro Guidewire, a next-generation...
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
Histotripsy demonstrated high technical success and an encouraging safety profile for the treatment of primary and secondary liver tumors in the first systematic review and meta-analysis to report the technology's clinical evidence.
BIRMINGHAM, Ala. — July 14, 2026 — Rampart, the global leader in enhanced radiation protection devices (ERPD), today welcomed the publication of a landmark multi-society expert consensus statement that calls for a fundamental shift in...
BIRMINGHAM, Ala. — July 14, 2026 — Rampart, the global leader in enhanced radiation protection devices (ERPD), today welcomed the publication of a landmark multi-society expert consensus statement that calls for a fundamental shift in...
